US Patent 11389511 Controlled-release CNP agonists with reduced side-effects
Patent 11389511 was granted and assigned to Ascendis Pharma on July, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Caroline Elisabeth Rasmussen0
Felix Cleemann0
Harald Rau0
Kennett Sprogøe0
Ulrich Hersel0
Edits on 23 Apr, 2023
Golden AI
Edits on 1 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 20 Jul, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+229 characters)
US Patent 11389511 Controlled-release CNP agonists with reduced side-effects
Article
The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11389511
Date of patent
July 19, 2022
Patent application number
16067070
Date Filed
January 5, 2017
Patent citations
Patent primary examiner
Find more entities like US Patent 11389511 Controlled-release CNP agonists with reduced side-effects
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
